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Aims of this work
• Obtaining high yields of soluble, stable and 
bioactive purified rhBMP-2.
• Evaluate the cytotoxicity and bioactivity of 
rhBMP-2 in stem cells and C2C12 cell line.
Introduction
Bone morphogenetic proteins have promoted great 
biomedical interest due to their ability in inducing 
new bone formation when used as powerful 
osteoinductive components of several late-stage 
bone grafting products. Recombinant human bone 
morphogenetic protein-2 (rhBMP-2) is obtained from 
mammalian cell expressing systems in low amounts 
or from bacteria inclusion bodies after time-
consuming refolding methods. Thus, there is a need 
to establish novel approaches for producing rhBMP-2 
in high yields by simple and cheap procedures.
Figure 1 – pET-25b expression vector. A novel approach 
allows secretion of soluble protein into periplasmatic space 
of E. coli allowing dimer formation.
Results
Solubilization and purification of rhBMP-2
Figure 2 – A) Silver stained reduced SDS-PAGE reveals purification 
growth factor to up 95%. B) Monomer, dimer and polymer detected by 
western-blot in non-reduced conditions.
Bioactivity in mesenchymal stem cells
Figure 3 – A) Alkaline phosphate (ALP) bioassay revealed increased 
levels of this late-marker of osteoblast differentiation after addition of 
rhBMP-2 to fat-derived human mesenchymal stem cells.
B) Tetrazolium salt (MTS) bioassay revealed no significant cytotoxicity of 
purified rhBMP-2 in fat-derived human mesenchymal stem cells.
Figure 4 – von Kossa bioassay revealed evidence of bone mineralizing 
nodules in rat bone marrow mesenchymal stem cells after two weeks of 
500 ng/ml stimulation with purified rhBMP-2. Magnif. 400x
Bioactivity in C2C12 cells
Figure 5 – Morphology of C2C12 cells after 5 days of addition of 
rhBMP-2 to the cell culture. A magnification of 400x was used.
Figure 6 – Semi-quantitative RT-PCR shows an increase in early 
markers of osteogenic differentiation (Runx2/Cbfa1, Smad-5 and 
Smad-1) after 5 days of cell culture with our BMP-2. A) negative 
control, B) 500ng/ml, C) 1000ng/ml, D) 2000ng/ml, E) 5000ng/ml, F) 
500ng/ml commercial BMP-2, G) 1000ng/ml commercial BMP-2. 
Figure 7 – BMP-2 signalling pathway which triggers differentiation of 
mesenchymal stem cells into osteoblasts.
Conclusions
¢ Recombinant human BMP-2 has been produced in monomer, dimer and polymer fractions and 
purified up to 95% purity.
¢ Absence of cytotoxicity was revealed by MTS bioassay. Evidence of bioactivity was shown in 
both mesenchymal stem cells and C2C12 cells by ALP bioassays and semi-quantitative RT- PCR.
¢The novel approach described herein shows to be a promising way for obtaining large amounts 
of partially purified rhBMP-2 that may be use in several future bone biomedical applications.
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